Antiretroviral treatment cohort analysis using time-updated CD4 counts: Assessment of bias with different analytic methods

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Kranzer, Katharina ^a,b   Lewis, James J ^a,c   White, Richard G ^a   Glynn, Judith R ^a   Lawn, Stephen D ^a,b   Middelkoop, Keren ^b,d   Bekker, Linda Gail ^b,d   Wood, Robin ^b,d  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c AURUM INSTITUTE   (South Africa)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTIC METHOD; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL STUDY; COHORT ANALYSIS; HAZARD RATIO; INCIDENCE; MEASUREMENT; SIMULATION; SYSTEMATIC ERROR; TIME; TIME UPDATED CD4 COUNT; TUBERCULOSIS; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; COMPUTER SIMULATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; EPIDEMIOLOGY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; RANDOMIZED CONTROLLED TRIAL; SOUTH AFRICA; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIAS (EPIDEMIOLOGY); CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; COMPUTER SIMULATION; HIV INFECTIONS; HUMANS; SOUTH AFRICA; TREATMENT OUTCOME; TUBERCULOSIS; VIRAL LOAD;

EID: 81255128948     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027763     Document Type: Article

References (34)

1. Hughes MD, Stein DS, Gundacker HM, Valentine FT, Phair JP, et al. (1994) Within-subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: implications for patient monitoring. J Infect Dis 169: 28-36.
2. Raboud JM, Montaner JS, Conway B, Haley L, Sherlock C, et al. (1996) Variation in plasma RNA levels, CD4 cell counts, and p24 antigen levels in clinically stable men with human immunodeficiency virus infection. J Infect Dis 174: 191-194.
3. Guarner J, Montoya P, del Rio C, Hernandez-Tepichin G, (1997) CD4+ T-lymphocyte variations in patients with advanced human immunodeficiency virus infection and counts below 100 cells per microliter. Cytometry 30: 178-180.
4. Lau B, Gange SJ, Moore RD, (2007) Interval and clinical cohort studies: epidemiological issues. AIDS Res Hum Retroviruses 23: 769-776.
5. Griffin JT, Fraser C, Gras L, de Wolf F, Ghani AC, (2006) The effect on treatment comparisons of different measurement frequencies in human immunodeficiency virus observational databases. Am J Epidemiol 163: 676-683.
6. Sanne I, Orrell C, Fox MP, Conradie F, Ive P, et al. (2010) Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet 376: 33-40.
7. National antiretroviral treatment guidelines, first ed Jacana (2004) Pretoria: National Department of Health, South Africa.
8. Rubin DB, (1987) Multiple Imputation for Nonresponse in Surveys. New York J. Wiley & Sons.
9. Nash D, Katyal M, Brinkhof MW, Keiser O, May M, et al. (2008) Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. Aids 22: 2291-2302.
10. Kranzer K, Lewis JJ, Ford N, Zeinecker J, Orrell C, et al. (2010) Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factors. J Acquir Immune Defic Syndr 55: e17-23.
11. Lawn SD, Myer L, Edwards D, Bekker LG, Wood R, (2009) Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 23: 1717-1725.
12. Van Rie A, Westreich D, Sanne I, (2011) Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies. J Acquir Immune Defic Syndr 56: 349-355.
13. Reekie J, Mocroft A, Sambatakou H, Machala L, Chiesi A, et al. (2008) Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure? AIDS 22: 2381-2390.
14. Lodi S, Guiguet M, Costagliola D, Fisher M, de Luca A, et al. (2010) Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion. Journal of the National Cancer Institute 102: 784-792.
15. Crum-Cianflone N, Hullsiek KH, Marconi V, Weintrob A, Ganesan A, et al. (2009) Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS 23: 41-50.
16. Crum-Cianflone N, Hullsiek KH, Satter E, Marconi V, Weintrob A, et al. (2009) Cutaneous malignancies among HIV-infected persons. Archives of Internal Medicine 169: 1130-1138.
17. Prosperi MC, Cozzi-Lepri A, Castagna A, Mussini C, Murri R, et al. (2010) Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study. Clinical Infectious Diseases 50: 1316-1321.
18. Seyler C, Messou E, Gabillard D, Inwoley A, Alioum A, et al. (2007) Morbidity before and after HAART initiation in Sub-Saharan African HIV-infected adults: a recurrent event analysis. AIDS Research & Human Retroviruses 23: 1338-1347.
19. Walker AS, Ford D, Gilks CF, Munderi P, Ssali F, et al. (2010) Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. Lancet 375: 1278-1286.
20. De Beaudrap P, Etard JF, Diouf A, Ndiaye I, Ndeye GF, et al. (2010) Incidence and determinants of new AIDS-defining illnesses after HAART initiation in a Senegalese cohort. BMC Infectious Diseases 10: 179.
21. Mocroft A, Ledergerber B, Zilmer K, Kirk O, Hirschel B, et al. (2007) Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score. AIDS 21: 1867-1875.
22. Collaboration of Observational HIVERESG, Bohlius J, Schmidlin K, Costagliola D, Fatkenheuer G, et al. (2009) Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study. Antiviral Therapy 14: 1065-1074.
23. Deuffic-Burban S, Losina E, Wang B, Gabillard D, Messou E, et al. (2007) Estimates of opportunistic infection incidence or death within specific CD4 strata in HIV-infected patients in Abidjan, Cote d'Ivoire: impact of alternative methods of CD4 count modelling. Eur J Epidemiol 22: 737-744.
24. Lawn SD, Badri M, Wood R, (2005) Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. Aids 19: 2109-2116.
25. Lawn SD, Little F, Bekker LG, Kaplan R, Campbel E, et al. (2009) Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS 23: 335-342.
26. Dunn D, Woodburn P, Duong T, Peto J, Phillips A, et al. (2008) Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults. J Infect Dis 197: 398-404.
27. Guiguet M, Porter K, Phillips A, Costagliola D, Babiker A, (2008) Clinical progression rates by CD4 cell category before and after the initiation of combination antiretroviral therapy (cART). Open AIDS J 2: 3-9.
28. Monforte A, Abrams D, Pradier C, Weber R, Reiss P, et al. (2008) HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 22: 2143-2153.
29. Engels EA, Pfeiffer RM, Landgren O, Moore RD, (2010) Immunologic and virologic predictors of AIDS-related non-hodgkin lymphoma in the highly active antiretroviral therapy era. Journal of Acquired Immune Deficiency Syndromes: JAIDS 54: 78-84.
30. Guiguet M, Bou, x00E, Cadranel J, Lang JM, et al. (2009) Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncology 10: 1152-1159.
31. Podlekareva D, Mocroft A, Kirk O, Reiss P, Aldins P, et al. (2008) Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/microl in the era of cART. Scandinavian Journal of Infectious Diseases 40: 908-913.
32. Sogaard OS, Lohse N, Gerstoft J, Kronborg G, Ostergaard L, et al. (2008) Hospitalization for pneumonia among individuals with and without HIV infection, 1995-2007: a Danish population-based, nationwide cohort study. Clinical Infectious Diseases 47: 1345-1353.
33. Phillips AN, Gazzard B, Gilson R, Easterbrook P, Johnson M, et al. (2007) Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS 21: 1717-1721.
34. Bruyand M, Thiebaut R, Lawson-Ayayi S, Joly P, Sasco AJ, et al. (2009) Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Clinical Infectious Diseases 49: 1109-1116.